Vanguard Group Inc Macrogenics Inc Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 4,213,114 shares of MGNX stock, worth $6.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,213,114
Previous 4,425,992
4.81%
Holding current value
$6.4 Million
Previous $5.62 Million
9.32%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding MGNX
# of Institutions
118Shares Held
52.3MCall Options Held
55.3KPut Options Held
35.9K-
Bellevue Group Ag Kuesnacht, V89.92MShares$15.1 Million0.27% of portfolio
-
Armistice Capital, LLC New York, NY5.96MShares$9.06 Million0.13% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$8.21 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$4.94 Million0.02% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.18MShares$4.83 Million0.2% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $93.4M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...